City Therapeutics, Inc. CTY

Full chart Compare

Set alert

18.84 USD +1.82 (+10.73%)

Nov 12, 2026, 11:23 AM EST

16.65 Day range 19.43

15.81 52-week range 23.88

YTD: -15.92%
1 year: -15.92%

News

2 days ago benzinga.com Jefferies Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $32 Jefferies analyst Maury Raycroft initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $32.
2 days ago benzinga.com This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated coverage on Mentari, MongoDB, Comfort Systems and Ross Stores; City Therapeutics received an early-stage biotech rating.
2 days ago benzinga.com Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46 Oppenheimer analyst Joseph Thomas initiates coverage on City Therapeutics (NASDAQ:CTY) with a Outperform rating and announces Price Target of $46.
2 days ago benzinga.com City Therapeutic Doses First Patient In Its Clinical Study Of CITY-RBP4 To Treat Stargardt Disease Type 1 City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, today announced that the first participant has…
2 days ago benzinga.com Goldman Sachs Initiates Coverage On City Therapeutics with Early-Stage Biotech Rating Goldman Sachs analyst Salveen Richter initiates coverage on City Therapeutics (NASDAQ:CTY) with a Early-Stage Biotech rating.
2 days ago globenewswire.com City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in Stargardt disease City's second program to advance into the…
2 days ago benzinga.com Stifel Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $34 Stifel analyst Paul Matteis initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $34.